Aarti Drugs trims Q1 Results Total Income of ₹555.34 Crore & Operating Profit ₹51.58 Crore

Aarti Drugs Q1 Results: Aarti Drugs' Q1 results for the fiscal period ending in June 2024 show a decline in performance when compared to both the previous quarter and the same period last year. The company’s total revenue decreased by 16.00% year-over-year (YoY), dropping from ₹661.11 crores in June 2023 to ₹555.34 crores in June 2024. This also reflects a quarter-on-quarter (QoQ) drop of 10.43% compared to the previous quarter (March 2023).

Aarti Drugs’ operating expenses, the total operating expense was ₹503.76 crores, which is a 14.56% drop YoY, as it was ₹589.63 crores in June 2023. Depreciation and amortization increased by 6.19% YoY, showing that the company has invested more in its assets, while other operating expenses decreased by 1.03% YoY.

Aarti Drugs’ operating income fell by 27.84% YoY, going from ₹71.48 crores in June 2023 to ₹51.58 crores in June 2024. Additionally, net income also declined by 30.52% YoY, from ₹47.84 crores in June 2023 to ₹33.24 crores in June 2024. Overall, the results indicate a challenging period for Aarti Drugs with significant year-over-year (YoY) declines in most financial metrics, highlighting the impact of market conditions.

Here are Aarti Drugs' Q1 results for the fiscal period ending June 2024, comparing both quarter-on-quarter (QoQ) and year-on-year (YoY) data:

(All figures in crores except per share values)

Source: Here 

For More Q1 Results check our Twitter Page

Visit our website for more Q1 results

Aarti Drugs Q1 Results 

Aarti Drugs' financial results for the quarter ending June 30, 2024, show a slight decrease in revenue compared to the same quarter in 2023. The company earned ₹49,296 lakhs from its operations in Q1 2024, which is lower than the ₹55,504 lakhs it earned in Q1 2023. Including other income, the total income for Q1 2024 stands at ₹53,071 lakhs, also down from ₹56,064 lakhs in Q1 2023.

Aarti Drugs’ expenses, the cost of materials consumed was ₹32,549 lakhs in Q1 2024, a decrease from ₹34,779 lakhs in Q1 2023. Employee benefit expenses and depreciation costs also remained relatively stable. Total expenses for Q1 2024 were ₹51,090 lakhs, slightly down from ₹51,247 lakhs in the previous year's quarter.

Aarti Drugs’ profit before tax (PBT) for Q1 2024 was ₹3,516 lakhs, which is lower than ₹4,308 lakhs in Q1 2023. After accounting for taxes, the net profit for Q1 2024 is ₹2,601 lakhs, showing a drop compared to ₹3,324 lakhs in Q1 2023.

Despite lower profits, Aarti Drugs’ earnings per share (EPS) for Q1 2024 were ₹2.93. Aarti Drugs saw a decline in revenue and profit but managed to control its expenses during the quarter.

 Here's the financial data for Aarti Drugs for the quarter ending June 30, 2024, presented in table format: 

Aarti Drugs Financial Performance

Aarti Drugs has made recent changes to its financial performance. The company's market cap stands at ₹4,897 crore, with a current stock price of ₹533. It experienced a 52-week high of ₹635 and a low of ₹430. The stock has a price-to-earnings (P/E) ratio of 37.9, which indicates how the market views its earnings potential compared to its price. The book value per share is ₹128, reflecting the company's net asset value. 

Here’s the financial data you shared in a table format:

Quarterly Results

The Aarti Drugs table shows financial data for the company's performance over three quarters: December 2023, March 2024, and June 2024. It details sales, expenses, and profits, including operating profit and net profit. The operating profit margin (OPM %) indicates how efficiently the company makes money from sales. Interest and depreciation costs are listed, as well as the company's profit before tax and net profit after tax. 

Here’s the table for Dec 2023, Mar 2024, and Jun 2024:

(Figures in Rs. Crores)

About Aarti Drugs 

Aarti Drugs, founded in 1984, is a significant player in the pharmaceutical industry, operating under the larger Aarti Group of Industries, which is valued at $900 million. The company's main facilities are located in the Tarapur Industrial Development Corporation (MIDC) area in Maharashtra, which is close to its manufacturing plants. Aarti Drugs specializes in producing Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, and Specialty Chemicals, and also creates Formulations through its wholly-owned subsidiary, Pinnacle Life Science Private.

Aarti Drugs of API products includes Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, and Ofloxacin. For Specialty Chemicals, they offer Benzene Sulphonyl Chloride and Methyl Nicotinate. The company is known for its strong research and development division, which helps them stay at the forefront of the industry.

Aarti Drugs has established a solid reputation over the years and is now focusing on expanding its production capacity. The growth in private health insurance and rising consumer spending on medicines is expected to drive the demand for generics, benefiting the company. All of their manufacturing units are GMP certified, and they are working on obtaining ISO 9002 certification for all facilities, with one unit already approved. Their goal is to be the preferred choice in the expanding market by ensuring high-quality products and timely delivery.